Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoietic cell transplantation recipients-Reference-Cited by-同舟云学术

Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoietic cell transplantation recipients

Published:2018-08-06 Issue:4 Volume:82 Page:717-721
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Akiyama Kana,Kume Tetsuo^ORCID,Fukaya Masafumi,Shiki Ikue,Enami Terukazu,Tatara Raine,Shino Michihiro,Ikeda Takashi

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-018-3659-8/fulltext.html

Reference27 articles.

1. Kim SW, Mori SI, Tanosaki R, Fukuda T, Kami M, Sakamaki H, Yamashita T, Kodera Y, Terakura S, Taniguchi S, Miyakoshi S, Usui N, Yano S, Kawano Y, Nagatoshi Y, Harada M, Morishima Y, Okamoto S, Saito AM, Ohashi Y, Ueda R, Takaue Y (2009) Busulfex (i.v. BU) and CY regimen before SCT: Japanese-targeted phase II pharmacokinetics combined study. Bone Marrow Transplant 43:611–617

2. Bredeson C, LeRademacher J, Kato K, Dipersio JF, Agura E, Devine SM, Appelbaum FR, Tomblyn MR, Laport GG, Zhu X, McCarthy PL, Ho VT, Cooke KR, Armstrong E, Smith A, Rizzo JD, Burkart JM, Pasquini MC (2013) Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood 122:3871–3878

3. Lee JH, Joo YD, Kim H, Ryoo HM, Kim MK, Lee GW, Lee JH, Lee WS, Park JH, Bae SH, Hyun MS, Kim DY, Kim SD, Min YJ, Lee KH (2013) Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol 31:701–709

4. Eberly AL, Anderson GD, Bubalo JS, McCune JS (2008) Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy 28:1502–1510

5. Floeter AE, McCune JS (2017) Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients. J Oncol Pharm Pract 23:344–349

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT);Bone Marrow Transplantation;2024-09-13

2. Impact of prophylactic echinocandin on the development of neurological complications in patients receiving busulfan‐containing conditioning regimens for stem cell transplantation: A single‐center retrospective study;Pediatric Transplantation;2024-04-10

3. Optimal regimen of levetiracetam for prevention of busulfan-induced seizure in patients undergoing hematopoietic stem cell transplantation: A review of available evidence;Journal of Oncology Pharmacy Practice;2023-02-27

4. Individualizing busulfan dose in specific populations and evaluating the risk of pharmacokinetic drug-drug interactions;Expert Opinion on Drug Metabolism & Toxicology;2023-02-01

5. Impact of valproic acid on busulfan pharmacokinetics: In vitro assessment of potential drug-drug interaction;PLOS ONE;2023-01-25